Glycans: The Aging Biomarker That Predicts Disease a Decade Early

IgG N-glycans explain up to 58% of the variance in chronological age — a stronger predictive signal than telomere length — and shifts in glycan profiles can precede diabetes onset by up to a decade before clinical symptoms appear.

Why Glycans Are Getting Serious Attention Now

Most longevity biomarker discussions center on telomeres, epigenetic clocks, or inflammatory markers like CRP. Glycans have been a background research topic for years, but a convergence of large-scale data and new mechanistic evidence is moving them to the front. GlycanAge, co-founded by Professor Gordan Lauc of the University of Zagreb, has now accumulated data from more than 300,000 samples — large enough to surface patterns that smaller cohort studies cannot resolve.

What makes this moment distinct is the combination of predictive power and reversibility. A biomarker that predicts risk and also responds measurably to interventions within a year is clinically actionable in a way that most aging clocks are not.

The Mechanism and the Data

Glycans are complex sugar molecules that attach to proteins and lipids, altering how those molecules behave. IgG N-glycans — glycans attached to immunoglobulin G antibodies — are particularly relevant because they modulate the inflammatory activity of those antibodies. As people age, glycan profiles shift toward pro-inflammatory configurations, a process researchers describe as a contributor to “inflammaging”: the chronic, low-grade inflammatory state increasingly recognized as central to cardiovascular disease, metabolic dysfunction, and neurodegenerative conditions.

The 300,000+ sample dataset from GlycanAge shows that these glycan shifts predict cardiovascular events better than standard lipid markers and precede diabetes onset by up to 10 years. That predictive window — detecting metabolic dysregulation a decade before clinical presentation — represents a meaningful departure from conventional cardiometabolic screening, which typically identifies risk after physiological changes are already well established.

The reversibility data is where the field becomes genuinely interesting. GlycanAge shifts toward a younger glycan profile have been observed after bariatric surgery, and caloric restriction has been shown to partially reverse pro-aging plasma glycan signatures. Professor Lauc has stated: “If there is a significant lifestyle change, or a developing disease, the GlycanAge can change for even more than a decade within a single year.”

A 2025 Fudan University study extended the mechanistic picture into a model system: IgG modified with young-signature N-glycans (IgG-Ny) administered to 80-week-old mice reduced IL-6 and TNF-α and decreased senescence markers in brain, kidney, and lung tissue. That is not a human intervention, but it provides a mechanistic bridge between the observational association and a possible therapeutic direction.

On the clinical infrastructure side, St. Catherine Hospital in Croatia has become the first hospital globally to integrate glycan-based biomarkers into routine cardiometabolic risk screening. The GlycanAge clinical conference on inflammaging is scheduled for June 20, 2026 in Croatia.

For context on how glycan testing fits alongside genetic and epigenetic approaches, see the Stack Archive analysis of genetic testing for longevity and the earlier piece on immune digital twin platforms.

Source: Longevity Technology

Content created with AI assistance and reviewed for accuracy.